EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation



CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation



Drug Metabolism and Disposition: the Biological Fate of Chemicals 30(1): 74-85



Here we report the phase I metabolism of the rationally designed Janus kinase-3 (JAK) inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131; JANEX-1). JANEX-1 was metabolized by the cytochrome P450 enzymes CYP1A1 and CYP1A2 in a regioselective fashion to form the biologically inactive 7-O-demethylation product 4-(4'-hydroxyphenyl)-amino-6-methoxy-7-hydroxyquinazoline (JANEX-1-M). Our molecular modeling studies indicated that the CYP1A family enzymes bind and demethylate JANEX-1 at the C-7 position of the quinazoline ring since the alternative binding conformation with demethylation at the C-6 position would result in a severe steric clash with the binding site residues. The metabolism of JANEX-1 to JANEX-1-M in pooled human liver microsomes followed Michaelis-Menten kinetics with V(max) and K(m) values (mean +/- S.D.) of 34.6 +/- 9.8 pmol/min/mg and 107.3 +/- 66.3 microM, respectively. alpha-Naphthoflavone and furafylline, which both inhibit CYP1A2, significantly inhibited the formation of JANEX-1-M in human liver microsomes. There was a direct correlation between CYP1A activities and the magnitude of JANEX-1-M formation in the liver microsomes from different animal species. A significantly increased metabolic rate for JANEX-1 was observed in Aroclor 1254-, beta-naphthoflavone-, and 3-methylcholanthrene-induced microsomes but not in clofibrate-, dexamethasone-, isoniazid-, and phenobarbital-induced microsomes. The formation of JANEX-1-M in the presence of baculovirus-expressed CYP1A1 and 1A2 was consistent with Michaelis-Menten kinetics. The systemic clearance of JANEX-1-M was much faster than that of JANEX-1 (5525.1 +/- 1926.2 ml/h/kg versus 1458.0 +/- 258.6 ml/h/kg). Consequently, the area under the curve value for JANEX-1-M was much smaller than that for JANEX-1 (27.5 +/- 8.0 versus 94.8 +/- 18.4 microM. h; P < 0.001).

(PDF emailed within 1 workday: $29.90)

Accession: 045420726

Download citation: RISBibTeXText

PMID: 11744615



Related references

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition 30(1): 74-85, 2002

In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clinical Cancer Research 5(10): 2954-2962, 1999

Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1). Arzneimittel-Forschung 53(9): 648-654, 2003

Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). Journal of Pharmacology and Experimental Therapeutics 295(3): 912-926, 2000

Pharmacokinetics and in vivo toxicity of Janus kinase 3 inhibitor WHI-P131 -amino-6,7-Dimethoxyquinazoline. Blood 94(10 SUPPL 1 PART 2): 197b, Nov 15, 1999

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107(1): 176-183, 2005

Islet allograft rejection is prevented by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, September, 2000

Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharmaceutical Research 16(1): 117-122, 1999

Prevention of development of type 1 diabetes in NOD mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, September, 2000

Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Arzneimittel-Forschung 53(9): 648-654, 2003

Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4- amino-6,7-dimethoxyquinazoline. Journal of Pharmacology & Experimental Therapeutics 295(3): 912-926, December, 2000

Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131). Journal of Chromatography B 727(1-2): 205-212, 1999

Insights into the structural basis of the GADD45beta-mediated inactivation of the JNK kinase, MKK7/JNKK2. Journal of Biological Chemistry 282(26): 19029-19041, 2007

Insights into the Structural Basis of the GADD45b-mediated Inactivation of the JNK Kinase, MKK7/JNKK2. The Journal of Biological Chemistry 282(26): 029-41, 2007

Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nature Structural and Molecular Biology 14(6): 535-539, 2007